Regeneron Tops Estimates as Dupixent and High‑Dose Eylea Drive Revenue Gains
Regeneron reported second-quarter revenue and profit that exceeded Wall Street expectations, driven by robust global sales of Dupixent and rising uptake of a higher-dose formulation of Eylea in the U.S. The company also completed repayment of an outstanding development balance to Sanofi, a move cited as supportive of margin improvement for the rema…